Takeda Pharmaceutical Co Ltd ADR (TAK)

Healthcare · Drug Manufacturers - Specialty & Generic
$18.10 +1.63% on the day Market cap $57.3B 52-week range $12.99 to $19.10 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Takeda Pharmaceutical Co Ltd ADR's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

C

Five factors scored 1 to 9 from TAK's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation7
Profitability5
Growth2
Financial health3
Cash efficiency7

Key numbers

P/E (trailing)47.7x
P/E (forward)11.4x
Price / free cash flow0.08x
EV / EBITDA9.37x
Price / sales0.01x
Price / book1.17x
Revenue growth+7.5%
Operating margin7.5%
Net margin2.4%
Return on equity1.6%
Dividend yield3.6%
Debt / equity1.05x

Results from SEC filings

Fiscal years, from Takeda Pharmaceutical Co Ltd ADR's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$3.20T$3.57T$4.03T$4.26T$4.58T
Net income$376.0B$230.1B$317.0B$144.1B$107.9B
Free cash flow$774.5B$937.1B$343.5B$235.6B$709.3B
EPS (diluted)$238.96$145.87$201.94$91.16$67.23
Operating margin15.9%12.9%12.2%5.0%7.5%

Where the revenue comes from

Revenue by products, fiscal 2026.

ENTYVIO$958.0B21%
Immunoglobulin$790.6B18%
TAKHZYRO$223.9B5%
Others$208.0B5%
VYVANSE/ELVANSE$203.2B5%
GATTEX/REVESTIVE$145.7B3%

Superinvestors who own TAK

From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Charles Brandes
Brandes Investment Partners, LP
Added $73M0.51%Q2 2026
Cliff Asness
AQR Capital Management
Added $24M0.01%Q2 2026
Richard Pzena
Pzena Investment Management
Added $606,2530.00%Q2 2026

Insider buying

Open-market purchases by Takeda Pharmaceutical Co Ltd ADR's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of TAK in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when TAK trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Takeda Pharmaceutical Co Ltd ADR insiders buying the stock?

No open-market insider purchases of TAK in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Takeda Pharmaceutical Co Ltd ADR?

3 of the superinvestors Investingly tracks hold TAK in their latest 13F, including Charles Brandes, Cliff Asness, Richard Pzena.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.